GlycoMimetics, Inc. (GLYC)
Largest Insider Buys in Sector
GLYC Stock Price History Chart
GLYC Stock Performance
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Insider Activity of GlycoMimetics, Inc.
Over the last 12 months, insiders at GlycoMimetics, Inc. have bought $173,415 and sold $0 worth of GlycoMimetics, Inc. stock.
On average, over the past 5 years, insiders at GlycoMimetics, Inc. have bought $4.34M and sold $4.4M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rock Edwin (Chief Medical Officer) — $169,081. Hahn Brian M. (SVP Finance, CFO) — $4,335.
The last purchase of 115,000 shares for transaction amount of $30,717 was made by Rock Edwin (Chief Medical Officer) on 2024‑06‑21.
List of Insider Buy and Sell Transactions, GlycoMimetics, Inc.
| 2024-06-21 | Rock Edwin | Chief Medical Officer | 115,000 0.1787% | $0.27 | $30,717 | +16.71% | ||
| 2024-06-20 | Rock Edwin | Chief Medical Officer | 190,000 0.2799% | $0.25 | $48,108 | +6.64% | ||
| 2024-06-18 | Hahn Brian M. | SVP Finance, CFO | 17,500 0.0252% | $0.25 | $4,335 | +8.24% | ||
| 2023-09-22 | Rock Edwin | Chief Medical Officer | 30,403 0.0463% | $1.38 | $41,956 | +21.99% | ||
| 2023-09-21 | Rock Edwin | Chief Medical Officer | 35,000 0.0544% | $1.38 | $48,300 | +24.28% | ||
| 2023-05-17 | Sale | Hahn Brian M. | SVP Finance, CFO | 3,700 0.0059% | $1.95 | $7,215 | -15.69% | |
| 2023-05-10 | JUNIUS DANIEL M | director | 30,000 0.0441% | $1.56 | $46,800 | -1.14% | ||
| 2023-05-08 | Johnson Bruce S | SVP & Chief Commercial Officer | 13,500 0.0237% | $1.57 | $21,195 | +18.24% | ||
| 2023-02-24 | Invus Public Equities, L.P. | 10 percent owner | 100,000 0.1667% | $1.70 | $170,000 | -5.33% | ||
| 2023-02-23 | Invus Public Equities, L.P. | 10 percent owner | 200,000 0.3399% | $1.75 | $350,760 | -6.14% | ||
| 2023-02-22 | Invus Public Equities, L.P. | 10 percent owner | 150,000 0.2504% | $1.79 | $268,995 | -9.83% | ||
| 2023-02-21 | Invus Public Equities, L.P. | 10 percent owner | 50,000 0.0798% | $1.85 | $92,500 | -16.41% | ||
| 2023-02-17 | Invus Public Equities, L.P. | 10 percent owner | 200,000 0.3006% | $1.71 | $341,000 | -14.89% | ||
| 2023-02-16 | Invus Public Equities, L.P. | 10 percent owner | 315,266 0.4849% | $1.68 | $531,129 | -11.81% | ||
| 2023-02-15 | Invus Public Equities, L.P. | 10 percent owner | 1M 2.3501% | $2.16 | $2.16M | +5.59% | ||
| 2023-02-09 | Invus Public Equities, L.P. | 10 percent owner | 11,451 0.0189% | $3.24 | $37,123 | -50.92% | ||
| 2023-01-26 | Sale | SANDELL SCOTT D | director | 3M 4.6279% | $3.12 | $9.36M | -52.24% | |
| 2023-01-25 | Sale | SANDELL SCOTT D | director | 652,016 1.1375% | $3.26 | $2.13M | -48.39% | |
| 2023-01-05 | Sale | SANDELL SCOTT D | director | 71,362 0.1255% | $2.76 | $196,859 | -38.46% | |
| 2023-01-04 | Sale | SANDELL SCOTT D | director | 101,984 0.1684% | $2.91 | $296,743 | -45.21% |
Insider Historical Profitability
| Rock Edwin | Chief Medical Officer | 680403 0.583% | $0.29 | 7 | 0 | <0.0001% |
| Hahn Brian M. | SVP Finance, CFO | 70643 0.0825% | $0.29 | 2 | 3 | +32.26% |
| Invus Public Equities, L.P. | 10 percent owner | 8589064 13.3384% | $0.29 | 8 | 0 | <0.0001% |
| BVF PARTNERS L P/IL | 10 percent owner | 4980812 7.735% | $0.29 | 3 | 0 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4702791 7.3032% | $0.29 | 1 | 2 | <0.0001% |
| BARRETT M JAMES | 4702791 7.3032% | $0.29 | 1 | 2 | <0.0001% | |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10 percent owner | 4702791 7.3032% | $0.29 | 1 | 2 | <0.0001% |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 4093377 6.3568% | $0.29 | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | director | 2237196 3.4743% | $0.29 | 1 | 8 | <0.0001% |
| HENOS MICHAEL A | director | 469454 0.729% | $0.29 | 2 | 4 | +27.18% |
| Magnani John L. | SVP of Research, CSO | 366078 0.5685% | $0.29 | 1 | 4 | +32.26% |
| King Rachel K. | President, CEO | 356064 0.553% | $0.29 | 0 | 1 | |
| Thackray Helen M. | SVP Clinical Development, CMO | 148615 0.2308% | $0.29 | 0 | 9 | |
| Johnson Bruce S | SVP & Chief Commercial Officer | 138980 0.2158% | $0.29 | 1 | 0 | +18.24% |
| JUNIUS DANIEL M | director | 93250 0.1448% | $0.29 | 5 | 0 | +18.64% |
| Andrews Patricia S | director | 45250 0.0703% | $0.29 | 1 | 0 | <0.0001% |
| Girard Armand | SVP, Chief Business Officer | 29161 0.0453% | $0.29 | 1 | 1 | +32.26% |
| Semerjian Harout | Chief Executive Officer | 25000 0.0388% | $0.29 | 1 | 0 | +32.26% |
| PEARSON TIMOTHY R | director | 24650 0.0383% | $0.29 | 1 | 0 | +32.26% |
| Goldberg Mark Alan | director | 11497 0.0179% | $0.29 | 1 | 0 | +23.55% |
Institutional Investor Ownership
| Bvf Inc Il | $28.63M | 14.81 | 9.54M | 0% | +$0 | 0.21 | |
| Artal Group S A | $25.77M | 13.32 | 8.59M | 0% | +$0 | 0.14 | |
| Nea Management Company Llc | $11.51M | 5.95 | 3.84M | -19.51% | -$2.79M | 0.13 | |
| Octagon Capital Advisors LP | $9M | 4.65 | 3M | 0% | +$0 | 1.18 | |
| The Vanguard Group | $8.29M | 4.29 | 2.76M | +14.04% | +$1.02M | <0.0001 | |
| AXA | $4.76M | 2.46 | 1.59M | +0.03% | +$1,329.00 | 0.01 | |
| Goldman Sachs | $3.34M | 1.73 | 1.11M | +21.25% | +$586,059.00 | <0.01 | |
| Millennium Management LLC | $2.24M | 1.16 | 746,954 | +1,820.78% | +$2.12M | <0.01 | |
| BlackRock | $2.2M | 1.14 | 732,567 | -0.33% | -$7,248.00 | <0.0001 | |
| Susquehanna International Group | $1.66M | 0.86 | 554,594 | +397.43% | +$1.33M | <0.01 | |
| Geode Capital Management | $1.52M | 0.78 | 505,147 | +5.48% | +$78,811.60 | <0.0001 | |
| Acadian Asset Management | $991,000.00 | 0.51 | 330,526 | -38.92% | -$631,581.63 | <0.01 | |
| Jane Street Capital | $867,825.00 | 0.45 | 289,275 | +406.23% | +$696,396.00 | <0.01 | |
| Qube Research & Technologies | $661,044.00 | 0.34 | 220,348 | +4,440.45% | +$646,485.00 | <0.01 | |
| Marshall Wace | $652,503.00 | 0.34 | 217,501 | +1,588.02% | +$613,848.00 | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $542,361.00 | 0.28 | 180,787 | +26.11% | +$112,284.00 | <0.01 | |
| State Street | $537,795.00 | 0.28 | 179,265 | -4.02% | -$22,500.00 | <0.0001 | |
| Bridgeway Capital Management | $505,800.00 | 0.26 | 168,600 | -14.5% | -$85,800.00 | 0.01 | |
| Verition Fund Management Llc | $487,284.00 | 0.25 | 162,428 | New | +$487,284.00 | 0.01 | |
| Hrt Financial Llc | $467,000.00 | 0.24 | 155,830 | New | +$467,000.00 | <0.01 | |
| Man Group Plc | $449,577.00 | 0.23 | 149,859 | New | +$449,577.00 | <0.01 | |
| Renaissance Technologies | $425,000.00 | 0.22 | 141,700 | +13.87% | +$51,755.82 | <0.01 | |
| Citigroup | $413,001.00 | 0.21 | 137,667 | +539.48% | +$348,417.00 | <0.0001 | |
| Northern Trust | $386,271.00 | 0.2 | 128,757 | +15.73% | +$52,509.00 | <0.0001 | |
| Sargent Investment Group Llc | $324,000.00 | 0.17 | 108,000 | +86.21% | +$150,000.00 | 0.08 | |
| Morgan Stanley | $309,264.00 | 0.16 | 103,088 | +198.71% | +$205,731.00 | <0.0001 | |
| Adage Capital Partners Gp L L C | $300,000.00 | 0.16 | 100,000 | 0% | +$0 | <0.01 | |
| Simplex Trading Llc | $271,000.00 | 0.14 | 90,652 | +25.13% | +$54,428.99 | 0.01 | |
| JPMorgan Chase | $253,872.00 | 0.13 | 84,624 | +5,146.37% | +$249,033.00 | <0.0001 | |
| American Century Investments | $190,926.00 | 0.1 | 63,642 | New | +$190,926.00 | <0.0001 | |
| LINSCO PRIVATE LEDGER CORP | $174,000.00 | 0.09 | 58,000 | +41.46% | +$51,000.00 | <0.0001 | |
| Point72 Asia Singapore Pte Ltd | $155,604.00 | 0.08 | 51,868 | New | +$155,604.00 | 0.02 | |
| Intellectus Partners | $152,160.00 | 0.08 | 50,720 | 0% | +$0 | 0.04 | |
| Bank of America | $152,829.00 | 0.08 | 50,943 | +154.84% | +$92,859.00 | <0.0001 | |
| Cubist Systematic Strategies | $149,394.00 | 0.08 | 49,798 | New | +$149,394.00 | <0.01 | |
| Letko Brosseau | $135,750.00 | 0.07 | 45,250 | 0% | +$0 | <0.01 | |
| Y Intercept Hong Kong Ltd | $129,390.00 | 0.07 | 43,130 | +62.31% | +$49,674.00 | 0.01 | |
| Balyasny Asset Management Llc | $121,671.00 | 0.06 | 40,557 | New | +$121,671.00 | <0.0001 | |
| IEQ Capital | $115,089.00 | 0.06 | 38,363 | 0% | +$0 | <0.01 | |
| Jefferies Financial Group | $114,600.00 | 0.06 | 38,200 | New | +$114,600.00 | <0.01 | |
| ExodusPoint Capital Management, LP | $107,000.00 | 0.06 | 35,698 | -62.72% | -$180,024.85 | <0.01 | |
| OMERS | $91,800.00 | 0.05 | 30,600 | New | +$91,800.00 | <0.01 | |
| Two Sigma Advisers LP | $87,900.00 | 0.05 | 29,300 | -82.28% | -$408,300.00 | <0.0001 | |
| Group One Trading | $86,037.00 | 0.04 | 28,679 | -8.24% | -$7,722.00 | <0.01 | |
| Tower Research Capital | $70,866.00 | 0.04 | 23,622 | +719.64% | +$62,220.00 | <0.01 | |
| Dimensional Fund Advisors | $69,468.00 | 0.04 | 23,156 | New | +$69,468.00 | <0.0001 | |
| Brevan Howard Capital Management Lp | $70,017.00 | 0.04 | 23,339 | New | +$70,017.00 | 0.01 | |
| Charles Schwab | $67,083.00 | 0.04 | 22,361 | 0% | +$0 | <0.0001 | |
| Squarepoint Ops LLC | $60,945.00 | 0.03 | 20,315 | New | +$60,945.00 | <0.0001 | |
| Belvedere Trading LLC | $61,395.00 | 0.03 | 20,465 | New | +$61,395.00 | <0.01 |